Related Experiment Video

Updated: Jul 23, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K

State-of-the-art document on optimal contemporary management of cardiomyopathies

Petar M Seferović1,2, Marija Polovina1,3, Giuseppe Rosano4

  • 1Faculty of Medicine, Belgrade University, Belgrade, Serbia.

European Journal of Heart Failure
|July 20, 2023
PubMed

Insights

This expert consensus summarizes current and novel treatments for cardiomyopathies, including dilated, hypertrophic, restrictive, and arrhythmogenic types. Evidence-based therapies aim to improve patient outcomes by targeting disease mechanisms.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Cardiomyopathies are major causes of heart disease, affecting morbidity and mortality.
  • Advances in understanding genetic factors and pathophysiology have refined diagnosis and risk assessment.
  • Targeted medications and standard care offer improved outcomes for various cardiomyopathies.

Purpose of the Study:

  • To provide a practical guide to cardiomyopathy treatment.
  • To integrate novel therapeutic concepts with established care principles.
  • To tailor treatment based on individual patient etiology and presentation.

Main Methods:

  • Expert consensus from the Heart Failure Association workshop (March 18, 2021).
  • Review of evidence-based novel therapeutic concepts.
  • Integration of established principles of care for cardiomyopathies.

Main Results:

  • Contemporary treatment strategies for dilated, hypertrophic, restrictive, and arrhythmogenic cardiomyopathies are outlined.
  • Novel targeted therapies and standard care approaches are discussed.
  • Emphasis on personalized treatment plans based on specific cardiomyopathy types.

Conclusions:

  • Current therapeutic strategies, combining novel agents and standard care, hold promise for improving outcomes in cardiomyopathies.
  • A nuanced, individualized approach to treatment is essential.
  • Continued research and expert consensus are vital for advancing cardiomyopathy care.

Keywords:
AetiologyArrhythmogenic cardiomyopathyDilated cardiomyopathyHypertrophic cardiomyopathyManagementMortalityRestrictive cardiomyopathyTreatment

More Related Videos

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.3K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.2K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12